Close this search box.

A new report from the Institute for Clinical and Economic Review says oral semaglutide treatment for people with Type 2 diabetes isn’t cost effective. But the report undervalues several key factors.

View the Graphic

Leave a Reply

Your email address will not be published. Required fields are marked *